As CROs and clinical outsourcing grow, it seems that subject recruitment and participation in clinical trials are lagging, as the American Association of Cancer Research (AACR) has shown. A survey conducted by market research firm Industry Standard Research shows that nearly 90% of surveyed drugmakers would prefer reaching patient recruitment goals at least 10% faster over cutting Phase II or Phase III trial costs 20%, as Ed Silverman details in his blog Pharmalot. As Silverman further explains, dissatisfaction in the field may explain why many pharma companies and drugmakers are taking the initiative to handle the recruitment process themselves, rather than bestowing that duty on CROs. Blog